clinical trial · NCT07387198
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·phase2·not yet recruiting·n = 135
Merkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IINeoadjuvant ImmunotherapyCemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesPlacebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.
brief summary
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
started
Jun 1, 2026
primary completion
Dec 31, 2029
completion
Jul 31, 2031
last updated
Apr 17, 2026
official title
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab - A Randomized, Double-blind, Placebo-controlled, Non-comparative Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol